Cardarine vs Trenbolone
Limited Research vs Moderate Research
compatible Researched · 90% Cardarine (GW-501516) is commonly used alongside trenbolone to counteract one of its most notorious side effects: severely reduced cardiovascular endurance. Trenbolone substantially impairs aerobic capacity, and cardarine's PPAR-delta agonism can partially restore endurance performance. This combination is popular among users who want trenbolone's anabolic benefits without completely sacrificing conditioning work.
Molecular Data
Cardarine Trenbolone
Weight 453.50 Da 270.37 Da (base)
Half-life ~16-24 hours ~3 days (acetate)
Type PPAR-delta agonist (C21H18F3NO3S2) 19-nortestosterone derivative (C18H22O2), trienone steroid
Key Benefits
Cardarine
01 Dramatic increase in endurance capacity through enhanced fatty acid oxidation in skeletal muscle
02 Promotes fat loss by shifting metabolic fuel preference toward fatty acid utilization over glucose
03 Improves lipid profiles: increases HDL cholesterol, decreases LDL cholesterol, and lowers triglycerides
04 Non-hormonal mechanism -- does not suppress testosterone or require post-cycle therapy
05 No androgenic side effects (no hair loss, no prostate stimulation, no virilization in women)
06 Long half-life (16-24 hours) permits convenient once-daily oral dosing
07 May offset lipid disruption caused by SARMs or anabolic steroids when used in combination
Trenbolone
01 Exceptional lean muscle mass accrual with minimal water retention due to non-aromatizing profile
02 Dramatic body recomposition capability -- simultaneous muscle gain and fat loss even in caloric deficit
03 Approximately five times the anabolic and androgenic potency of testosterone (500:500 ratio)
04 Powerful anti-catabolic effects through glucocorticoid receptor antagonism, protecting muscle during dieting
05 Significant increases in strength across all compound movements, often rapid in onset
06 Enhanced nutrient partitioning, directing calories toward lean tissue accretion over fat storage
07 Pronounced muscle hardness, density, and vascularity due to absence of estrogenic water retention
08 Increased IGF-1 production in muscle tissue, amplifying growth signaling pathways
Dosing Protocols
Cardarine
10-20 mg/day / Once daily (oral)
Trenbolone
200-400 mg/week / Every other day (acetate) or 2x per week (enanthate)
Recomposition - Moderate (Acetate) 200-300 mg/week (50-75 mg every other day) Every other day
Advanced Cutting (Acetate) 300-400 mg/week (75-100 mg every other day) Every other day
Lean Bulk (Enanthate) 200-400 mg/week 2x per week
Contest Preparation - Advanced 300-500 mg/week Every other day (acetate) or 2x per week (enanthate)
Side Effects
Cardarine
Headaches (typically transient, most common in the first week)
Mild gastrointestinal discomfort (nausea, loose stools, or stomach upset, usually dose-dependent and transient)
Trenbolone
Insomnia and severely disrupted sleep architecture (one of the most universally reported side effects, affecting the majority of users)
Night sweats, often drenching, requiring sheet changes
Significantly reduced cardiovascular endurance and aerobic capacity
Increased aggression, irritability, and shortened temper
Anxiety and restlessness, particularly at higher doses
Tren cough: acute, intense coughing fit lasting 30-90 seconds immediately after injection, caused by a small amount of oil entering a blood vessel
Dark-colored urine (oxidized metabolites; not necessarily indicative of kidney damage but should be monitored)
Elevated body temperature and increased sweating throughout the day
Acne and oily skin, particularly on shoulders, back, and chest
Accelerated hair loss in those genetically predisposed to male pattern baldness
Profoundly suppressive of natural testosterone production (near-complete HPT axis shutdown)
Increased heart rate and elevated blood pressure
Contraindications
Personal or family history of cancer (the rodent carcinogenicity data warrants extreme caution in individuals with elevated cancer risk)
Pregnancy or potential pregnancy
Breastfeeding
Pre-existing liver disease (limited safety data)
Individuals under 18 years of age
First steroid cycle or limited anabolic steroid experience (trenbolone is strictly an advanced-only compound)
Pre-existing cardiovascular disease, cardiomyopathy, or significant cardiac risk factors
History of mental health conditions: anxiety disorders, depression, bipolar disorder, or psychotic episodes
Liver disease or significantly elevated liver enzymes
Kidney disease or impaired renal function
Uncontrolled hypertension
Polycythemia (hematocrit above 54% at baseline)
Prostate cancer or history of hormone-sensitive cancers
Active or recent substance abuse (trenbolone's psychological effects can exacerbate addictive behaviors)
Pregnancy or potential for pregnancy in female partners (extremely virilizing compound)
Research Evidence
Cardarine Trenbolone
Status Limited Research Moderate Research
References 5 studies 5 studies
Latest May 2017 January 2023
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.